In conclusion, this study demonstrates the feasibility of non-invasively predicting EGFR T790M mutation at diagnosis in NSCLC patients following treatment with a first- or second-generation EGFR-TKI using a ML model integrating radiomic features and clinical characteristics. Here, EGFR is linked to non-small cell lung carcinoma.